Dr. Enrico Tiacci is a physician scientist who established an independent translational and clinical research program in leukemias and lymphomas at the University and Hospital of Perugia, where he is Associate Professor of Hematology. His most relevant scientific contributions to pathogenesis, diagnosis and therapy of blood cancers span Hodgkin lymphoma, acute myeloid leukemia and, within the field of HCL, include the discovery of BRAF mutation as the genetic cause of this disease, its diagnostic exploitation and its therapeutic targeting in the clinic, which radically changed the understanding of HCL and considerably improved its treatment. For his achievements (mostly published in the highly influential New England Journal of Medicine), Dr. Tiacci received several prestigious national and international prizes as well as scientific grants from the most competitive international research agencies, including the European Research Council and Blood Cancer United.
Enrico Tiacci MD
University of Perugia. Department of Medicine and Surgery
Project Title
BRAF inhibition as an alternative to chemotherapy in the treatment strategy of hairy cell leukemia BRAF and BCL2 coinhibition with vemurafenib and venetoclax as a rational, short, all-oral targeted therapy for relapsed/refractory hairy cell leukemia
Program
Hairy Cell Leukemia Research Initiative